返回 
加入收藏
米力农注射液治疗高血压性心脏病伴心力衰竭的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 米力农注射液治疗高血压性心脏病伴心力衰竭的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察米力农注射液治疗高血压性心脏病伴心力衰竭的疗效及安全性。方法：将120例高血压性心脏病伴慢性心力衰竭患者按随机数字表法分为对照组与观察组，各60例。对照组患者接受常规治疗，包括控制血压、抗心力衰竭等对症处理；观察组患者在对照组基础上加用米力农注射液0.3 mg/kg，微量持续泵入，qd，连续5 d为1个疗程，每月治疗1个疗程，连续治疗6个月。两组患者均随访1年。观察两组患者治疗前，治疗3、6个月及治疗后1年6 min步行距离（6MWD）、血浆脑钠肽（BNP）、左室射血分数（LVEF）、心脏指数（CI）、左室舒张末期内径（LVEDD）、静息心率、坐位收缩压、坐位舒张压、再住院、心血管病死发生情况，并比较两组患者心功能改善疗效及不良反应发生率。结果：治疗前，两组患者6MWD、BNP、LVEF、CI、LVEDD、静息心率、坐位收缩压、坐位舒张压比较，差异均无统计学意义（P＞0.05）。治疗3、6个月及治疗后1年，两组患者6MWD、LVEF、CI均显著上升，BNP、LVEDD、静息心率、坐位收缩压、坐位舒张压均显著下降，且观察组改善程度显著优于对照组，差异有统计学意义（P＜0.05）。观察组患者心功能改善总有效率为90.00％，显著高于对照组的63.33％，差异有统计学意义（P＜0.05）。随访1年，观察组患者再住院率显著低于对照组，差异有统计学意义（P＜0.05）；心血管病死率比较，差异无统计学意义（P＞0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：米力农注射液治疗高血压性心脏病伴心力衰竭的疗效显著，能明显降低患者BNP和再住院率，改善预后，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe therapeutic efficacy and safety of Milrinone injection in the treatment of hypertensive heart disease complicated with heart failure. METHODS： A total of 120 patients with hypertensive heart disease complicated with chronic heart failure were randomized into control group and observation group according to random number table， with 60 cases in each group. Control group received routine therapy， including blood pressure controlling， anti-heart failure and other symptomatic treatment； observation group was additionally given Milrinone injection 0.3 mg/kg， continuous pump， qd. A treatment course lasted for 5 d. Both groups received one course of treatment each month for consecutive 6 months. Both groups were followed up for one year. 6 min walking distance （6MWD）， BNP， LVEF， CI， LVEDD， heart rate， sitting systolic blood pressure （SiSBP） and sitting diastolic blood pressure （SiDBP）， re-hospitalization rate and cardiovascular mortality were observed in 2 groups before treatment， after 3，6 months and 1 year of treatment； therapeutic efficacy of heart function and the incidence of ADR were compared between 2 groups. RESULTS： Before treatment， there was no statistical significance in 6MWD， BNP， LVEF， CI， heart rate， SiSBP and SiDBP between 2 groups； after 3 months， 6 months and 1 year of treatment， 6MWD， LVEF and CI of 2 groups were increased significantly， while BNP， LVEDD， resting heart rate， SiSBP and SiDBP were decreased significantly； the observation group was significantly better than the control group， with statistical significance （P＜0.05）. Total response rate of heart function was 90.00％ in observation group， which was significantly higher than 63.33％ in control group， with statistical significance （P＜0.05）. After 1 year of follow-up， re-hospitalization rate of observation group was significantly lower than that of control group， with statistical significance （P＜0.05）； there was no statistical significance in cardiovascular mortality （P＞0.05）. There were no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Milrinone injection shows good efficacy in the treatment of hypertensive heart disease complicated with heart failure， can significantly reduce BNP and re-hospitalization rate as well as improve prognosis with good safety. |
| 期刊： | 2017年第28卷第5期 |
| 作者： | 苏衡，王广艳，朱君 |
| AUTHORS： | SU Heng，WANG Guangyan，ZHU Jun |
| 关键字： | 米力农注射液；高血压性心脏病；心力衰竭；脑钠肽；预后 |
| KEYWORDS： | Milrinone injection； Hypertensive heart disease； Heart failure； BNP； Prognosis |
| 阅读数： | 757 次 |
| 本月下载数： | 8 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
